Summit Therapeutics closed at $16.17 on Nov 4, up 2.34%, 38.7% below its 52-week closing high. Volume of 4.3M shares was 0.84× its 20-day average (close to normal).
Split-adjusted performance: -6.6% over one month, -9.4% over six months, -11.3% over one year.
Short interest was 40.9M shares at the Oct 15 settlement (29.5% of float, 7.0 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| SMMTSummit Therapeutics | $16.17 | +2.34% | −9.4% | — | — | — | $12.90B | |
| ELANElanco Animal Health Incorporated | $25.31 | +3.01% | −3.3% | +10.2% | 3.9% | — | $12.65B | Compare |
| BMRNBioMarin Pharmaceuticals | $57.13 | +2.64% | +4.6% | +19.9% | 4.5% | 151.5 | $11.06B | Compare |
| BBIOBridgeBio Pharma | $77.89 | +5.21% | +14.4% | +192.6% | −23.5% | — | $15.17B | Compare |
| JAZZJazz Pharmaceuticals | $234.66 | +2.14% | +2.7% | +10.4% | −38.9% | 74.0 | $15.23B | Compare |
| TGTXTG Therapeutics | $61.63 | +1.45% | +46.8% | +70.3% | 3.2% | 21.4 | $9.43B | Compare |
| PTGXProtagonist Therapeutics | $143.37 | +2.23% | +37.9% | +3749.2% | 76.3% | 111.9 | $9.28B | Compare |
| SYRESpyre Therapeutics | $99.04 | −0.23% | +35.7% | — | — | — | $9.26B | Compare |
| MDGLMadrigal Pharmaceuticals | $400.43 | +1.04% | −25.8% | +50.1% | 12.9% | — | $9.25B | Compare |
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
